|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP2654748B1
(en)
*
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
EP2934516A4
(en)
*
|
2012-12-20 |
2016-07-20 |
Merck Sharp & Dohme |
3 ESTER 4 SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
|
|
US9643955B2
(en)
|
2012-12-20 |
2017-05-09 |
Merck Sharp & Dohme Corp. |
2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
|
|
EP2953944B1
(en)
*
|
2013-02-07 |
2017-04-26 |
Merck Patent GmbH |
Pyridazinone-amides derivatives
|
|
LT2953952T
(lt)
*
|
2013-02-07 |
2017-08-25 |
Merck Patent Gmbh |
Makrocikliniai piridazinono dariniai
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
TWI667233B
(zh)
*
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
SG11201605408RA
(en)
*
|
2014-01-10 |
2016-07-28 |
Aurigene Discovery Tech Ltd |
Indazole compounds as irak4 inhibitors
|
|
FI3805233T3
(fi)
|
2014-01-13 |
2024-04-17 |
Aurigene Oncology Ltd |
N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9926330B2
(en)
|
2014-09-30 |
2018-03-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
JO3705B1
(ar)
*
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
US10336707B2
(en)
|
2014-12-16 |
2019-07-02 |
Eudendron S.R.L. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
EA039043B1
(ru)
|
2015-04-22 |
2021-11-25 |
Райджел Фармасьютикалз, Инк. |
Пиразольные соединения и способ получения и применения данных соединений
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
UY36660A
(es)
|
2015-04-30 |
2016-11-30 |
Bayer Pharma AG |
Combinaciones de inhibidores de irak4
|
|
EP3423446B1
(de)
|
2016-03-03 |
2020-09-16 |
Bayer Pharma Aktiengesellschaft |
Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
UA123169C2
(uk)
|
2016-04-29 |
2021-02-24 |
Байєр Фарма Акцієнгезелльшафт |
Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
|
|
KR102409105B1
(ko)
|
2016-04-29 |
2022-06-16 |
바이엘 파마 악티엔게젤샤프트 |
인다졸의 합성
|
|
MY199070A
(en)
|
2016-06-01 |
2023-10-12 |
Bayer Pharma AG |
Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
DK3600270T3
(da)
|
2017-03-31 |
2023-07-10 |
Aurigene Oncology Ltd |
Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
CA3079292A1
(en)
|
2017-10-19 |
2019-04-25 |
Bayer Animal Health Gmbh |
Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
|
|
CA3079628A1
(en)
|
2017-10-31 |
2019-05-09 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
AU2020220333B2
(en)
|
2019-02-11 |
2025-10-16 |
Merck Patent Gmbh |
Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
JP2022539374A
(ja)
*
|
2019-06-27 |
2022-09-08 |
バイオジェン・エムエイ・インコーポレイテッド |
２ｈ－インダゾール誘導体及び疾患の処置におけるそれらの使用
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN121159524A
(zh)
|
2019-08-30 |
2025-12-19 |
里格尔药品股份有限公司 |
吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
KR102782229B1
(ko)
|
2019-10-02 |
2025-03-20 |
(주)카이노스메드 |
N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021084022A1
(en)
*
|
2019-10-31 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
|
|
CN114728976B
(zh)
|
2019-11-19 |
2024-08-16 |
豪夫迈·罗氏有限公司 |
用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
|
|
WO2021110614A1
(en)
|
2019-12-03 |
2021-06-10 |
F. Hoffmann-La Roche Ag |
HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
KR20240004476A
(ko)
|
2021-04-08 |
2024-01-11 |
쿠리스 인코퍼레이션 |
암 치료를 위한 병용 요법
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112023025403A2
(pt)
|
2021-06-25 |
2024-02-20 |
Korea Res Inst Chemical Tech |
Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
JP2025513716A
(ja)
|
2022-03-23 |
2025-04-30 |
ライジェル・ファーマシューティカルズ・インコーポレイテッド |
Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
|
|
KR102607237B1
(ko)
*
|
2023-06-07 |
2023-11-30 |
주식회사 젠센 |
신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
|
|
CN121816348A
(zh)
*
|
2023-08-11 |
2026-04-07 |
深圳众格生物科技有限公司 |
一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
|